ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
OS Therapies Incorporated

OS Therapies Incorporated (OSTX)

1.82
-0.02
(-1.09%)
1.78
-0.04
(-2.20%)

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.78
Bid
-
Ask
-
Volume
186,589
1.73 Day's Range 1.87
1.12 52 Week Range 7.00
Market Cap
Previous Close
1.84
Open
1.79
Last Trade
652
@
1.82
Last Trade Time
Financial Volume
$ 334,171
VWAP
1.7909
Average Volume (3m)
282,056
Shares Outstanding
28,097,697
Dividend Yield
-
PE Ratio
-4.78
Earnings Per Share (EPS)
-0.39
Revenue
-
Net Profit
-10.89M

About OS Therapies Incorporated

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adult... OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-tADC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Middletown, Delaware, USA
Founded
-
OS Therapies Incorporated is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker OSTX. The last closing price for OS Therapies was $1.84. Over the last year, OS Therapies shares have traded in a share price range of $ 1.12 to $ 7.00.

OS Therapies currently has 28,097,697 shares outstanding. The market capitalization of OS Therapies is $51.70 million. OS Therapies has a price to earnings ratio (PE ratio) of -4.78.

OSTX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.15.952380952381.682.071.65800721.94368019CS
40.15.952380952381.682.071.453243481.76072136CS
120.2113.37579617831.572.491.122820561.74821364CS
26-2.47-58.11764705884.2571.127278912.64463728CS
52-2.22-55.5471.124643862.76068856CS
156-2.22-55.5471.124643862.76068856CS
260-2.22-55.5471.124643862.76068856CS

OSTX - Frequently Asked Questions (FAQ)

What is the current OS Therapies share price?
The current share price of OS Therapies is $ 1.78
How many OS Therapies shares are in issue?
OS Therapies has 28,097,697 shares in issue
What is the market cap of OS Therapies?
The market capitalisation of OS Therapies is USD 51.7M
What is the 1 year trading range for OS Therapies share price?
OS Therapies has traded in the range of $ 1.12 to $ 7.00 during the past year
What is the PE ratio of OS Therapies?
The price to earnings ratio of OS Therapies is -4.78
What is the reporting currency for OS Therapies?
OS Therapies reports financial results in USD
What is the latest annual profit for OS Therapies?
The latest annual profit of OS Therapies is USD -10.89M
What is the registered address of OS Therapies?
The registered address for OS Therapies is 18 MANASSAS DRIVE, MIDDLETOWN, DELAWARE, 197093802
What is the OS Therapies website address?
The website address for OS Therapies is www.ostherapies.com
Which industry sector does OS Therapies operate in?
OS Therapies operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HUSAHouston American Energy Corp
$ 15.5499
(117.79%)
28.85M
GLLProShares UltraShort Gold
$ 20.6494
(94.81%)
1.16M
TMDETMD Energy Limited
$ 1.27
(69.85%)
85.11M
INDOIndonesia Energy Corporation Limited
$ 5.16
(45.76%)
38.52M
MXCMexco Energy Corp
$ 12.225
(44.16%)
444.35k
UGLProShares Ultra Gold
$ 37.4595
(-74.36%)
1.61M
ARCXTradr 2X Long ACHR Daily ETF
$ 18.93
(-29.86%)
509.2k
KNWKnow Labs Inc
$ 3.375
(-23.81%)
3.46M
SOARVolato Group Inc
$ 1.65
(-23.61%)
1.37M
VTAKCatheter Precision Inc
$ 0.349099
(-18.81%)
6.53M
DNNDenison Mines Corp
$ 1.635
(0.93%)
236.62M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 20.04
(-7.61%)
166.99M
EONREON Resources Inc
$ 0.5755
(19.65%)
166.35M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 1.64
(-3.24%)
154.68M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 10.17
(7.62%)
139.38M

OSTX Discussion

View Posts
velcro velcro 1 month ago
Johnny, we've got to wonder how such a rotten financial manager as GC can keep landing on his feet.
Hard luck research companies need people like GC with a good line of quality horse manure.
Learning what doesn't work creates more opportunity for the next experiment.
👍️0
Monksdream Monksdream 1 month ago
OSTX under $2
👍️0
swingingRichard swingingRichard 3 months ago
OSTX being promoted by some pr firm called RedChip on Bloomberg. 
👍️0
tw0122 tw0122 4 months ago
$1.92 ..The Company recently completed a $7.1 millionfinancing in January 2025 and has sufficient capital into mid 2026..
(2) sell the Priority Review Voucher (PRV) it would receive from the FDA BLA approval prior to the September 30, 2026 PRV deadline to a larger pharmaceutical company at prevailing market prices (most recent PRV sale transaction was $150 million), (3) commercialize OST-HER2 in osteosarcoma and (4) then expand the clinical development of OST-HER2 into breast cancer and other larger solid tumor indications for additional revenue potential.

👍️0
Rotten Johnny Rotten Johnny 4 months ago
too much debt AND the CBO is a lying POS shyster who destroys SH value



C-Suites my royal right butt cheek ...!

just look at what Gerald Commissiong did to AMBS and TOMDF

drove both into insolvency and stole everything he could via serial dilution from his SH's

its just that plain and simple...!



Gerald Commissiong - WAPOS
👍️ 1
tw0122 tw0122 4 months ago
Yes only played premarket to much debt here 
👍️0
Monksdream Monksdream 4 months ago
OSTX under $3
👍️0
Rotten Johnny Rotten Johnny 4 months ago
don't touch it...

unless you're Jack be nimble Jack be quick...

AJMHO
👍️ 1
tedpeele tedpeele 4 months ago
I'm seeing 1.6m float
👍️0
glenn1919 glenn1919 4 months ago
OSTX...................................................newone.....................................https://stockcharts.com/h-sc/ui?s=ostxp=W&yr=1&mn=3&dy=0&id=p96837884856
👍️0
tw0122 tw0122 4 months ago
$4.10 + 104% went to $5s last run January but profit taking hitting bigger now 
👍️0
Rotten Johnny Rotten Johnny 4 months ago
I wouldn't touch ANYTHING Gerald Commissiong is involved with...

did you see the last P&D they pulled in Dec., 24

AJMHO
👍️0
tw0122 tw0122 4 months ago
$3.36 + 70% Guess will find out later flip out time ..
 The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

👍️0
Rotten Johnny Rotten Johnny 4 months ago
interesting - wonder where they'll get their funding

and if it will be toxic - Gerald...?
👍️0
tw0122 tw0122 4 months ago
OSTK 3.06 + 52% 
👍️0
tw0122 tw0122 4 months ago
OSTX $2.30 + 15% .. NEW YORK--(BUSINESS WIRE)--Feb. 14, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of OST-HER2. 
👍️0
tw0122 tw0122 5 months ago
Didn't trade it but see you under $4 maybe lol thanks
👍️0
TheFinalCD TheFinalCD 5 months ago
$OSTX in yesterday's filing pic.twitter.com/2l25LO7e3J— brentkhack (@brentkhack_TX) January 15, 2025
👍️0
tw0122 tw0122 5 months ago
Lung action $8s + 92% 17m floater 
👍️0
Rotten Johnny Rotten Johnny 9 months ago
looking good Gerald...!

IMHO, you'll have this trading at $0.00028 in record time



here comes the Astoria Queens financial mafia wrecking crew to help assist you in your next financial debacle

so much for running TOMDF into insolvency and jumping ship to this firm which didn't last long:

Fortitude Advisors LLC

https://fortitudeadvisors.com/team/

"He is also the Chief Business Officer at OS Therapies, Inc. starting in 2024 and the Managing Partner at Fortitude Advisors LLC since 2019."

https://uk.marketscreener.com/insider/GERALD-COMMISSIONG-A19LFK/

I give Gerald Commissiong 6 months before OSTX fire's his arse - and for good measure...!

MOO pathetic
👍️0
Rotten Johnny Rotten Johnny 9 months ago
uh ho - Gerald Commissiong OSTX's new Chief Business Officer executive named...

and is the same old same old serial dilution 'scam artist' from AMBS & TOMDF

here we go again folks...!



buyers be ware - check these other 2 tickers for the catastrophic results by this Stanford Univ. Financial Engineering hack

https://ostherapies.com/leadership/

SMH - can't make this stuff up - sad but true...!

MOO tool
👍️0

Your Recent History

Delayed Upgrade Clock